Abbonarsi

Psychotropic use in elderly with cognitive impairment living in nursing homes - 08/07/17

Doi : 10.1016/j.eurpsy.2017.01.2069 
A.R. Ferreira 1, 2, S. Martins 2, , C. Dias 3, M.R. Simões 4, L. Fernandes 5
1 PhD Program in Clinical and Health Services Research/PDICSS, Health Information and Decision Sciences Department, Faculty of Medicine, University of Porto, Porto, Portugal 
2 CINTESIS–Center for Health Technology and Services Research, Faculty of Medicine, University of Porto, Porto, Portugal 
3 Health Information and Decision Sciences Department, FMUP, Center for Health Technology and Services Research/CINTESIS, Faculty of Medicine, University of Porto, Porto, Portugal 
4 Psychological Assessment Laboratory, CINEICC, Faculty of Psychology and Educational Sciences, University of Coimbra, Coimbra, Portugal 
5 Department of Clinical Neuroscience and Mental Health, CINTESIS, Faculty of Medicine, University of Porto, Porto, Portugal 

Corresponding author.

Riassunto

Introduction

Elderly patients in nursing homes (NH) are often prescribed medications for many physical and mental health problems, with polypharmacy. There is a considerable number of studies documenting this extensive prescription of psychotropic medication, despite the raised concerns about their overuse/misuse, due to serious adverse effects, including increased rate of cognitive decline associated with antipsychotics.

Aims

To characterize the prescription of psychotropics in elderly sample with cognitive impairment living in NH.

Methods

Elderly living in three Portuguese NH were included in this cross-sectional study. All residents were eligible, unless they were unwilling or unresponsive. Participants’ medication was obtained from medical records. Guidelines of ATC were used to categorize the drugs. Participants were assessed with MMSE and GDS.

Results

The sample included 172 elderly, mostly women (90%), with average of 81(sd=10) years and median lengths of stay of 3years. Overall, 79.1% used1 nervous system-acting drugs. Anxiolytics (54.7%), antidepressants (29.1%) and antipsychotics (23.3%) were the most frequent. The majority (58%) presented cognitive impairment (MMSE). Among those, 46.2% presented depression (GDS) and 79.6% took at least one drug for the CNS and 41.9%3. Antipsychotics were received by 26.5%, while 57.1% used anxiolytics, 31.6% antidepressants and 16.3% anti-dementia drugs. No significant relation between GDS and antidepressants was found.

Conclusion

This study confirms the high usage of CNS drugs in patients with cognitive impairment in NH. These rates were comparable with previous studies. Antidepressants appear to be under-used, which can be related to the under-recognition of depression. Also, potential harmful psychotropic drugs such as anxiolytics and antipsychotics are overused.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2017  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 41 - N° S

P. S174 - aprile 2017 Ritorno al numero
Articolo precedente Articolo precedente
  • Educational level influenced the gold standard diagnosis of late-life depression in the GreatAGE study
  • M. Lozupone, F. Veneziani, L. Lofano, I. Galizia, E. Stella, M. Copetti, S. Arcuti, A. Leo, R. Sardone, A. Grasso, M. Tursi, M.R. Barulli, R. Tortelli, R. Capozzo, F. Panza, D. Seripa, C. Bonfiglio, A.R. Osella, G. Logroscino
| Articolo seguente Articolo seguente
  • A systematic review of association between pain and suicidal behavior in elderly people
  • J. Santos, S. Martins, L.F. Azevedo, L. Fernandes

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.